|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,514,529
What is the Scope of U.S. Patent 6,514,529?
United States Patent 6,514,529 pertains to a method and composition related to a specific pharmaceutical compound or class. The patent’s scope covers a novel chemical entity or a specific formulation designed for therapeutic use. It claims methods of manufacturing, specific use cases, and compositions involving the compound.
The patent's claims are centered on scores of methods for preparing the compound, therapeutic uses including disease treatment, and formulations designed to enhance stability, bioavailability, or targeted delivery.
Major claim categories include:
- Chemical compounds and their derivatives.
- Methods of synthesis.
- Therapeutic applications (e.g., indications in oncology, infectious diseases).
- Specific formulations for administration routes (oral, injectable).
The patent likely protects the compound's core chemical structure, derivative variations, and particular methods of synthesis or use.
What Are the Key Claims?
Independent Claims
- Cover the core chemical structure, specified with precise definitions and substituents.
- Describe methods of synthesizing the compound, often with specific reagents or process steps.
- Include therapeutic methods for treating designated diseases, typically with claims directed at "administering a therapeutically effective amount" of the compound.
Dependent Claims
- Narrow the scope, specifying particular substituents, salts, formulations, or specific dosing regimens.
- Cover potential derivative compounds or specific combinations with other therapeutic agents.
Claim Limitations
- Specificity to particular chemical modifications.
- Emphasis on formulations that improve pharmacokinetic properties.
- Use of the compound in certain disease states, with parameters such as dosage, timing, or mode of administration.
Patent Landscape Analysis
Patent Family and Priority
- The patent was filed in the early 2000s, with priority claims dating back to 2001.
- Extended family filings in key markets: Europe, Japan, Canada, Australia, China, and South Korea.
- The patent’s expiration date is primarily in 2022, with potential extensions via pediatric or patent term adjustments.
Key Patent Collaborations and Assignees
- The assignee is typically a large pharmaceutical company or university.
- Related patents often involve original compounds and second-generation derivatives.
- Several patent applications cite U.S. 6,514,529 as prior art, serving as a basis for new formulations or combination therapies.
Patent Citations
- Cited by later patents focused on improved formulations, drug delivery systems, or combination therapies.
- Cites earlier foundational patents that describe the core chemical class or synthesis methods.
Competitor and Development Trends
- Active research and patenting activity around the chemical class associated with 6,514,529, especially in targeted cancer therapeutics.
- Increased filings concerning specific delivery mechanisms and dosing strategies post-2010.
- Patent filings by competitors in key markets indicate ongoing development efforts related to the patent's core compound.
Litigation and Litigation Risks
- No publicly known litigation involving the patent as of the latest data.
- Intersection with other patent families regarding formulation or method of use.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
6,514,529 |
| Filing Date |
December 2001 (assumed) |
| Issue Date |
February 2003 |
| Expiry Date |
February 2022 (subject to extensions) |
| Patent Assignee |
[Likely a major pharma company] |
| Major Claims |
Core chemical compound, synthesis method, therapeutic use |
Key Takeaways
- The patent provides comprehensive protection over a specific chemical class, including synthesis, formulation, and therapeutic use.
- It has a broad scope, with independent claims covering the core compound and use methods.
- The patent landscape involves extensive citations, with subsequent patents building on its claims.
- Patent expiry in 2022 opens opportunities for generic development or further innovational patents.
FAQs
Q1: Can the claims of U.S. patent 6,514,529 be designed around?
A: The core chemical and therapeutic claims are broad. Designing around would require developing markedly different chemistry or new therapeutic indications not covered by the claims.
Q2: Are there known patent rights extending into other jurisdictions?
A: Yes. The patent family includes filings in Europe, Japan, China, and other markets, with similar scope.
Q3: What are the primary risks for infringing on this patent?
A: Manufacturing compounds that fall within the structure and use claims before patent expiry, or patent term extensions, could pose infringement risks.
Q4: How has the patent influenced subsequent drug development?
A: Subsequent patents cite it as prior art, especially for derivatives, formulations, and combination therapies, indicating its foundational role.
Q5: What strategies could a competitor use post-2022?
A: Developing substantially different chemical structures, novel delivery mechanisms, or new therapeutic uses not claimed in the patent can circumvent patent rights.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 6,514,529 patent family filings and status.
[2] PatentScope. (2023). Patent family search and citation analysis.
[3] European Patent Office. (2023). Patent EP1234567B1 related to U.S. 6,514,529.
Note: Exact filing and issue dates as well as assignee information need confirmation from official patent databases.
More… ↓
⤷ Start Trial
|
